Navigation Links
ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study
Date:9/15/2010

nerally well tolerated at all dose levels; there were no serious or severe adverse events, and no discontinuations from study drug due to adverse events.
  • All 27 volunteers (100 percent) who were given VP20621 had positive non-toxigenic C. difficile stool cultures by day 6, suggesting that VP20621 rapidly colonizes the susceptible GI tract.
  • No patient dosed with VP20621 tested positive for toxin-producing strains of C. difficile during the 28-day study period.
  • By comparison, 5 of 9 subjects (56 percent) who received placebo (i.e. did not receive VP20621) tested positive for either toxin-negative or toxin-positive C. difficile during the study period.

    • "I am highly encouraged by the data from this Phase 1 study of VP20621, which for the first time support the tolerability and colonization effectiveness of non-toxigenic C. difficile, mimicking what we have inferred from observing colonization of patients with these organisms," commented Dale Gerding, M.D., Associate Chief of Staff for Research at the Hines VA Hospital.  "Colonization protection of VP20621 awaits demonstration in a Phase 2 clinical trial in CDI patients to confirm pre-clinical data and observational studies of natural colonization in humans that have demonstrated high levels of protection against CDI that approach 100%."

    "Previous animal and clinical observational studies have described the prevention of symptomatic CDI by colonization of the large bowel with non-toxin producing strains of C. difficile," commented Dr. Colin Broom, ViroPharma's chief scientific officer.  "We now know that VP20621 appears to behave similarly, rapidly colonizing the large bowel and potentially protecting it from colonization with dangerous toxin-producing strains of C. difficile. We are excited by these positive data and expect to move rapidly into Phase 2 studies with VP20621 in the coming months
    '/>"/>

    SOURCE ViroPharma Incorporated
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. ViroPharma to Present at Three Upcoming Healthcare Conferences
    2. ViroPharma to Present at the Natixis Bleichroeder Conference
    3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
    4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
    5. ViroPharma Announces Discontinuation of HCV-796 Development
    6. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
    7. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
    8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
    9. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
    10. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
    11. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/17/2013)... , May 17, 2013 Fuse Science, Inc. (OTCQB: ... company that is developing new, patent-pending technologies poised to redefine ... that it will hold a business update teleconference and webcast ... nd , 2013 at 4:30 PM ET. ... will host the call and will be joined by ...
    (Date:5/17/2013)... 2013  PENTAX Medical, a healthcare industry leader ... leader in ultrasound imaging, recently announced renewed collaborative ... further innovation in the development of Endoscopic Ultrasound ... and PENTAX Medical endoscopic portfolio have formed one ... systems. This agreement will continue to grow their ...
    (Date:5/17/2013)... -- Sanofi (EURONEXT: SAN and NYSE: SNY ) announced ... , examining the selective JAK2 inhibitor SAR302503 for myelofibrosis ... The primary endpoint assessed the proportion of patients achieving ... in previous trials, the most common adverse events were ... presented at an upcoming medical congress. ...
    Breaking Medicine Technology:Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 2PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6
    (Date:5/17/2013)... HealthDay Reporter , , FRIDAY, May 17 (HealthDay News) ... brain may make the call on which ear you ... The dominant side of your brain is where your ... human population is left-brain dominant, and those people tend ... who are right-brain dominant. In this study, scientists found ...
    (Date:5/17/2013)... 17, 2013 Fighting addiction is hard ... for diabetics, treatment is more difficult and complicated. Drug ... to monitor blood sugar levels and administer insulin when ... drug rehab for diabetics needs to have ... needs of the diabetic, and has experience caring for ...
    (Date:5/17/2013)... 17 (HealthDay News) -- Teen bullies are more likely ... finds. UT Dallas researchers analyzed several decades of ... All of them had similar working-class backgrounds and most ... were in their mid-50s. Nearly half of the ... years engaged in some form of criminal activity -- ...
    (Date:5/17/2013)... SportsFanPlayground.com is currently offering a new ... $319.99, nearly 20% off of the retail price. , The ... Adventures and Carnival Games, and a complementary 3-month Xbox Live ... Kinect Star Wars Bundle available for shipping. The Star Wars bundle ... 360 console, a custom white Kinect sensor, an Xbox 360 wired ...
    (Date:5/17/2013)... Guide to the DSM-5 explores all revisions to ... Manual, and shows clinicians how they can best ... most contentious resource. Written by a celebrated professor ... and new research to point out where DSM-5 ... the jury,s still out. Along the way, The ...
    Breaking Medicine News(10 mins):Health News:Cellphone Use May Reveal Your 'Dominant Brain' 2Health News:Cellphone Use May Reveal Your 'Dominant Brain' 3Health News:Above It All Treatment Center Helps Drug Addicts who are Type I and Type II Diabetics 2Health News:Above It All Treatment Center Helps Drug Addicts who are Type I and Type II Diabetics 3Health News:Xbox 360 Kinect Bundle 20% Off at SportsFanPlayground.com 2
    ... are banned for manufacture, import and use in India. ... use in the country but their manufacture is allowed ... to Information (RTI) Act. ,As India grapples ... productivity and environmental safety, the government has also acknowledged ...
    ... Manipur are literally holding the state to ransom with ... huge extortion notices slapped by rebels. ,Pharmacies ... until Sunday after a rebel group demanded Rs.10 million ... Association and the All Manipur Pharmaceutical and Druggists Association. ...
    ... poison that can kill, arsenic also can prolong the lives ... new study out Saturday found. ,"This study shows ... earlier in the course of treatment," said Dr. Bayard Powell, ... and the lead author of the research delivered at the ...
    ... The last two decades have seen modest overall improvements in ... However, according to researchers at The University of Texas M. ... the rates for black women; differences in life expectancy between ... study, presented today (June 3) at the 43rd annual American ...
    ... the journal Health Psychology, by the American Psychological Association ... or mean disposition tend to have compromised lung ... were ruled out as possible causes of lung dysfunction. ... White 18-30 year olds from four metropolitan areas (sampled ...
    ... new study co-led by an urologist and a radiation ... specialty of the physician patients see can influence ... analyzed men with localized prostate cancer. It found that ... urologist are more likely to undergo surgery to remove ...
    Cached Medicine News:Health News:25 Pesticides Banned in India, Others Face Partial Curbs 2Health News:Manipur Pharmacies Shut Down Fearing Separatist Threats 2Health News:Advanced Breast Cancer: Study Reveals White and Black Women Have Different Survival Rates 2Health News:Unhealthy Lungs Linked to Hostility? 2Health News:Early Prostate Cancer: Specialty of Physician Influences Type of Therapy Received 2Health News:Early Prostate Cancer: Specialty of Physician Influences Type of Therapy Received 3
    Patient-Centered Therapy that promotes natural cardiac function....
    ... The Alliance Catheter Delivery ... manipulation, and stabilization of the ... Alliance CDS has a patented ... for quick and easy access ...
    ... throughout the world are facing difficult times ... of the blood supply in the face ... donor base. Clearly, these centers must find ... manage their existing donor pools, and to ...
    The COBE 2991 Cell Processor provides reliable, automated cell processing, with the control you need to get reproducible results in your lab. This versatile machine offers users reliability and multi...
    Medicine Products: